RepurpOS

Tinnitus

Disease intelligence for Tinnitus: 118 alterations and 219 ranked therapeutics from curated public databases.

US DALYs176.4KWHO GHE 2021 · all ages
Global DALYs3.71MWHO GHE 2021 · worldwide
US mortality120 deaths/yrWHO GHE 2021
Global mortality760 deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionSpontaneous resolution in 50-60% of acute tinnitus (<3 months) without treatment; chronic tinnitus (>3 months): only…
Best-intervention remissionCognitive behavioural therapy (CBT): 50-60% reduction in tinnitus-related distress (not sound elimination); tinnitus…
Gap sizeVery large — no pharmacological treatment exists; CBT and TRT are evidence-based but massively under-accessed
Primary barrierbiological + access
Full remission profile →

Disease overview

Alterations
118
Molecular (A)
100
Clinical (B–E)
18
Direct drugs
43
Via biomarker
177
Natural agents
0
Natural products
31
Merged ranked
219
With trial/literature evidence
25

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Seeds, GreenMedInfo · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission
Spontaneous resolution in 50-60% of acute tinnitus (<3 months) without treatment; chronic tinnitus (>3 months): only 10-15% spontaneous resolution; habituated tinnitus (not distressing) in 75% at 5 years but sound remains in most
Best-intervention remission
Cognitive behavioural therapy (CBT): 50-60% reduction in tinnitus-related distress (not sound elimination); tinnitus retraining therapy (TRT): 80% improvement in distress over 18 months; hearing aids for comorbid hearing loss: modest tinnitus reduction; sound therapy (masking): symptom relief without cure
Drug-free remission
Relapse after remission
Chronicity
Gap size
Very large — no pharmacological treatment exists; CBT and TRT are evidence-based but massively under-accessed
Primary barrier
biological + access
Barrier detail: No effective pharmacotherapy exists (multiple drug classes tried and failed); sound therapy and CBT are the only evidence-based interventions but trained tinnitus therapists are scarce; most patients are told to 'live with it'; digital CBT for tinnitus (iCBT) emerging as scalable solution

Last SoC change: 2023 — Lenire (bimodal neurostimulation device) cleared in some markets; 2022 FDA De Novo cleared for SAINT protocol-based devices; no pharmacotherapy approved; CBT/TRT standard since 1990s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: EFO: HP_0000360 · ORPHA: ORPHA:79135

Alterations

Showing 80 of 118 · Types A (molecular) through E (functional)

NameTypeSubtypeDirection FrequencyEvidenceSourcesLinks
ACAN
aggrecan
Molecular Gene Emerging Open Targets
ADPGK
ADP dependent glucokinase
Molecular Gene Emerging Open Targets
ANXA4
annexin A4
Molecular Gene Emerging Open Targets
BBS4
Bardet-Biedl syndrome 4
Molecular Gene Emerging Open Targets
BCAR3
BCAR3 adaptor protein, NSP family member
Molecular Gene Emerging Open Targets
BDNF
brain derived neurotrophic factor
Molecular Gene Emerging Open Targets
BRD3
bromodomain containing 3
Molecular Gene Emerging Open Targets
Beck Depression Inventory Scales & PROs Clinical scale Emerging ClinicalTrials.gov
CACNA1A
calcium voltage-gated channel subunit alpha1 A
Molecular Gene Emerging Open Targets
CACNA1B
calcium voltage-gated channel subunit alpha1 B
Molecular Gene Emerging Open Targets
CACNA1C
calcium voltage-gated channel subunit alpha1 C
Molecular Gene Emerging Open Targets
CACNA1D
calcium voltage-gated channel subunit alpha1 D
Molecular Gene Emerging Open Targets
CACNA1E
calcium voltage-gated channel subunit alpha1 E
Molecular Gene Emerging Open Targets
CACNA1F
calcium voltage-gated channel subunit alpha1 F
Molecular Gene Emerging Open Targets
CACNA1G
calcium voltage-gated channel subunit alpha1 G
Molecular Gene Emerging Open Targets
CACNA1H
calcium voltage-gated channel subunit alpha1 H
Molecular Gene Emerging Open Targets
CACNA1I
calcium voltage-gated channel subunit alpha1 I
Molecular Gene Emerging Open Targets
CACNA1S
calcium voltage-gated channel subunit alpha1 S
Molecular Gene Emerging Open Targets
CACNA2D1
calcium voltage-gated channel auxiliary subunit alpha2delta 1
Molecular Gene Emerging Open Targets
CACNA2D2
calcium voltage-gated channel auxiliary subunit alpha2delta 2
Molecular Gene Emerging Open Targets
CACNA2D3
calcium voltage-gated channel auxiliary subunit alpha2delta 3
Molecular Gene Emerging Open Targets
CACNA2D4
calcium voltage-gated channel auxiliary subunit alpha2delta 4
Molecular Gene Emerging Open Targets
CACNB1
calcium voltage-gated channel auxiliary subunit beta 1
Molecular Gene Emerging Open Targets
CACNB2
calcium voltage-gated channel auxiliary subunit beta 2
Molecular Gene Emerging Open Targets
CACNB3
calcium voltage-gated channel auxiliary subunit beta 3
Molecular Gene Emerging Open Targets
CACNB4
calcium voltage-gated channel auxiliary subunit beta 4
Molecular Gene Emerging Open Targets
CACNG1
calcium voltage-gated channel auxiliary subunit gamma 1
Molecular Gene Emerging Open Targets
CACNG2
calcium voltage-gated channel auxiliary subunit gamma 2
Molecular Gene Emerging Open Targets
CACNG3
calcium voltage-gated channel auxiliary subunit gamma 3
Molecular Gene Emerging Open Targets
CACNG4
calcium voltage-gated channel auxiliary subunit gamma 4
Molecular Gene Emerging Open Targets
CACNG5
calcium voltage-gated channel auxiliary subunit gamma 5
Molecular Gene Emerging Open Targets
CACNG6
calcium voltage-gated channel auxiliary subunit gamma 6
Molecular Gene Emerging Open Targets
CACNG7
calcium voltage-gated channel auxiliary subunit gamma 7
Molecular Gene Emerging Open Targets
CACNG8
calcium voltage-gated channel auxiliary subunit gamma 8
Molecular Gene Emerging Open Targets
CD180
CD180 molecule
Molecular Gene Emerging Open Targets
CHRNA10
cholinergic receptor nicotinic alpha 10 subunit
Molecular Gene Emerging Open Targets
CHRNA9
cholinergic receptor nicotinic alpha 9 subunit
Molecular Gene Emerging Open Targets
CNTNAP5
contactin associated protein family member 5
Molecular Gene Emerging Open Targets
COL11A1
collagen type XI alpha 1 chain
Molecular Gene Emerging Open Targets
CRIP3
cysteine rich protein 3
Molecular Gene Emerging Open Targets
Change from Baseline in Tinnitus symptoms assessed by questionnaires Scales & PROs Clinical scale Emerging ClinicalTrials.gov
Change in Tinnitus Handicap Inventory (THI) Lab / Clinical Lab value Emerging ClinicalTrials.gov
DBN1
drebrin 1
Molecular Gene Emerging Open Targets
DNM1
dynamin 1
Molecular Gene Emerging Open Targets
DNTTIP2
deoxynucleotidyltransferase terminal interacting protein 2
Molecular Gene Emerging Open Targets
EEFSEC
eukaryotic elongation factor, selenocysteine-tRNA specific
Molecular Gene Emerging Open Targets
FAM110B
family with sequence similarity 110 member B
Molecular Gene Emerging Open Targets
FBXL17
F-box and leucine rich repeat protein 17
Molecular Gene Emerging Open Targets
FER
FER tyrosine kinase
Molecular Gene Emerging Open Targets
FHIP1A
FHF complex subunit HOOK interacting protein 1A
Molecular Gene Emerging Open Targets
GABRA1
gamma-aminobutyric acid type A receptor subunit alpha1
Molecular Gene Emerging Open Targets
GABRA2
gamma-aminobutyric acid type A receptor subunit alpha2
Molecular Gene Emerging Open Targets
GABRA3
gamma-aminobutyric acid type A receptor subunit alpha3
Molecular Gene Emerging Open Targets
GABRA4
gamma-aminobutyric acid type A receptor subunit alpha4
Molecular Gene Emerging Open Targets
GABRA5
gamma-aminobutyric acid type A receptor subunit alpha5
Molecular Gene Emerging Open Targets
GABRA6
gamma-aminobutyric acid type A receptor subunit alpha6
Molecular Gene Emerging Open Targets
GABRB1
gamma-aminobutyric acid type A receptor subunit beta1
Molecular Gene Emerging Open Targets
GABRB2
gamma-aminobutyric acid type A receptor subunit beta2
Molecular Gene Emerging Open Targets
GABRB3
gamma-aminobutyric acid type A receptor subunit beta3
Molecular Gene Emerging Open Targets
GABRD
gamma-aminobutyric acid type A receptor subunit delta
Molecular Gene Emerging Open Targets
GABRG1
gamma-aminobutyric acid type A receptor subunit gamma1
Molecular Gene Emerging Open Targets
GABRG3
gamma-aminobutyric acid type A receptor subunit gamma3
Molecular Gene Emerging Open Targets
GABRP
gamma-aminobutyric acid type A receptor subunit pi
Molecular Gene Emerging Open Targets
GABRQ
gamma-aminobutyric acid type A receptor subunit theta
Molecular Gene Emerging Open Targets
GATB
glutamyl-tRNA amidotransferase subunit B
Molecular Gene Emerging Open Targets
GRIN1
glutamate ionotropic receptor NMDA type subunit 1
Molecular Gene Emerging Open Targets
GRIN2A
glutamate ionotropic receptor NMDA type subunit 2A
Molecular Gene Emerging Open Targets
GRIN2B
glutamate ionotropic receptor NMDA type subunit 2B
Molecular Gene Emerging Open Targets
GRIN2C
glutamate ionotropic receptor NMDA type subunit 2C
Molecular Gene Emerging Open Targets
GRIN2D
glutamate ionotropic receptor NMDA type subunit 2D
Molecular Gene Emerging Open Targets
GRIN3A
glutamate ionotropic receptor NMDA type subunit 3A
Molecular Gene Emerging Open Targets
GRIN3B
glutamate ionotropic receptor NMDA type subunit 3B
Molecular Gene Emerging Open Targets
Hospital Anxiety and Depression Scale (HADS) Scales & PROs Clinical scale Emerging ClinicalTrials.gov
Hyperacusis Questionnaire (HQ) Scales & PROs Clinical scale Emerging ClinicalTrials.gov
Insomnia severity index (ISI) Scales & PROs Clinical scale Emerging ClinicalTrials.gov
LUZP2
leucine zipper protein 2
Molecular Gene Emerging Open Targets
MSRA
methionine sulfoxide reductase A
Molecular Gene Emerging Open Targets
MUC6
mucin 6, oligomeric mucus/gel-forming (gene/pseudogene)
Molecular Gene Emerging Open Targets
MYC
MYC proto-oncogene, bHLH transcription factor
Molecular Gene Emerging Open Targets
NDRG1
N-myc downstream regulated 1
Molecular Gene Emerging Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
DIAZEPAM Small molecule Approved Strong 100
4 Trial pubs 2 RCT
View evidence

Published literature

Open Targets, ChEMBL
ACETAZOLAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
ADAPALENE Repurposing Small molecule Approved Strong 95 DGIdb
ALPRAZOLAM Repurposing Small molecule Approved Strong 95
4 Trial pubs 3 RCT
View evidence

Published literature

DGIdb
AMITRIPTYLINE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
AMLODIPINE BENZOATE Repurposing Small molecule Approved Strong 95 DGIdb
AMLODIPINE BESYLATE Repurposing Small molecule Approved Strong 95 DGIdb
AMLODIPINE BESYLATE Repurposing Small molecule Approved Strong 95 DGIdb
AMLODIPINE MALEATE Repurposing Small molecule Approved Strong 95 DGIdb
AMPHETAMINE Repurposing Small molecule Approved Strong 95 ChEMBL
ARGIPRESSIN Repurposing Small molecule Approved Strong 95 DGIdb
ARSENIC TRIOXIDE Repurposing Small molecule Approved Strong 95 DGIdb
ATENOLOL Repurposing Small molecule Approved Strong 95 DGIdb
BACLOFEN Repurposing Small molecule Approved Strong 95 DGIdb
BEPRIDIL Repurposing Small molecule Approved Strong 95 DGIdb
BEPRIDIL HYDROCHLORIDE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
BICALUTAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
BORTEZOMIB Repurposing Small molecule Approved Strong 95 DGIdb
CAMPTOTHECIN Repurposing Small molecule Approved Strong 95 DGIdb
CAPSAICIN Repurposing Small molecule Approved Strong 95 DGIdb
CARBACHOL Repurposing Small molecule Approved Strong 95 ChEMBL
CELECOXIB Repurposing Small molecule Approved Strong 95
2 pubs
View evidence
DGIdb
CETUXIMAB Repurposing Small molecule Approved Strong 95 DGIdb
CHLORPROMAZINE Repurposing Small molecule Approved Strong 95 DGIdb
CINNARIZINE Repurposing Small molecule Approved Strong 95
6 Trial pubs 5 RCT
View evidence

Published literature

DGIdb
CIPROFLOXACIN Repurposing Small molecule Approved Strong 95 ChEMBL
CITALOPRAM Repurposing Small molecule Approved Strong 95 DGIdb
CLEVIDIPINE Repurposing Small molecule Approved Strong 95 DGIdb
CLOMIPRAMINE Repurposing Small molecule Approved Strong 95 DGIdb
CLOMIPRAMINE Repurposing Small molecule Approved Strong 95 ChEMBL
COLCHICINE Repurposing Small molecule Approved Strong 95 DGIdb
CORTICOTROPIN Repurposing Small molecule Approved Strong 95 DGIdb
DACTINOMYCIN Repurposing Small molecule Approved Strong 95 DGIdb
DEHYDRATED ALCOHOL Repurposing Small molecule Approved Strong 95 DGIdb
DESIPRAMINE Repurposing Small molecule Approved Strong 95 DGIdb
DICHLORPHENAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
DIDANOSINE Repurposing Small molecule Approved Strong 95 DGIdb
DIETHYLSTILBESTROL Repurposing Small molecule Approved Strong 95 DGIdb
DIETHYLSTILBESTROL Repurposing Small molecule Approved Strong 95 ChEMBL
DILTIAZEM HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
DILTIAZEM MALATE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
DONEPEZIL HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
DOXORUBICIN HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
DRONABINOL Repurposing Small molecule Approved Strong 95 DGIdb
DRONEDARONE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
DULOXETINE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
EMPAGLIFLOZIN Repurposing Small molecule Approved Strong 95 DGIdb
EPIRUBICIN Repurposing Small molecule Approved Strong 95 ChEMBL
EPOETIN ALFA Repurposing Small molecule Approved Strong 95 DGIdb
ESTAZOLAM Repurposing Small molecule Approved Strong 95
1 pubs
View evidence
DGIdb
DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
CAROVERINE Small molecule Phase III Moderate 80 Open Targets
ESKETAMINE HYDROCHLORIDE Small molecule Phase III Moderate 80 Open Targets
NERAMEXANE Small molecule Phase III Moderate 80 Open Targets
NERAMEXANE MESYLATE Small molecule Phase III Moderate 80 Open Targets
OXYTOCIN Biologic Phase III Moderate 80 Open Targets
AMITRIPTYLINE Small molecule Phase II Emerging 60 Open Targets
BREXANOLONE Small molecule Phase II Emerging 60 Open Targets
DIAZEPAM Small molecule Phase II Emerging 60
4 Trial pubs 2 RCT
View evidence

Published literature

Open Targets
EBSELEN Small molecule Phase II Emerging 60 Open Targets
ETANERCEPT Biologic Phase II Emerging 60 Open Targets
GABAPENTIN Small molecule Phase II Emerging 60 Open Targets
GACYCLIDINE Small molecule Phase II Emerging 60 Open Targets
HYDROXYCHLOROQUINE Small molecule Phase II Emerging 60 Open Targets
INCOBOTULINUMTOXINA Small molecule Phase II Emerging 60 Open Targets
KETAMINE Small molecule Phase II Emerging 60 Open Targets
PAROXETINE Small molecule Phase II Emerging 60 Open Targets
PERPHENAZINE Small molecule Phase II Emerging 60 Open Targets
PREDNISOLONE Small molecule Phase II Emerging 60 Open Targets
SELURAMPANEL Small molecule Phase II Emerging 60 Open Targets
VARDENAFIL Small molecule Phase II Emerging 60 Open Targets
VESTIPITANT Small molecule Phase II Emerging 60 Open Targets
ZINC ION Small molecule Phase II Emerging 60 Open Targets
ACAMPROSATE Small molecule Phase I Emerging 35 Open Targets
CANNABINOL Small molecule Phase I Emerging 35 Open Targets
DEXAMETHASONE Small molecule Phase I Emerging 35 Open Targets
LIDOCAINE Small molecule Phase I Emerging 35 Open Targets
METHYLPREDNISOLONE Small molecule Phase I Emerging 35 Open Targets
MODAFINIL Small molecule Phase I Emerging 35 Open Targets
OLANZAPINE Small molecule Phase I Emerging 35 Open Targets
PREDNISONE Small molecule Phase I Emerging 35 Open Targets
BETAHISTINE Small molecule Preclinical Emerging 15 Open Targets
CILOSTAZOL Small molecule Preclinical Emerging 15 Open Targets
CURCUMIN Small molecule Preclinical Emerging 15 Open Targets
GINKGO Small molecule Preclinical Emerging 15 Open Targets
LUTEOLIN Small molecule Preclinical Emerging 15 Open Targets
OXITRIPTAN Small molecule Preclinical Emerging 15 Open Targets
PALMIDROL Small molecule Preclinical Emerging 15 Open Targets
PIMOZIDE Small molecule Preclinical Emerging 15 Open Targets
PIRIBEDIL Small molecule Preclinical Emerging 15 Open Targets
PIRIBEDIL Small molecule Preclinical Emerging 15 Open Targets
DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
ACETAZOLAMIDE Repurposing via ANXA4 Small molecule Approved Strong 95 ChEMBL
ADAPALENE Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
ALPRAZOLAM Repurposing via BRD3 Small molecule Approved Strong 95
4 Trial pubs 3 RCT
View evidence

Published literature

DGIdb
AMITRIPTYLINE HYDROCHLORIDE Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
AMLODIPINE BENZOATE Repurposing via CACNA1F Small molecule Approved Strong 95 DGIdb
AMLODIPINE BESYLATE Repurposing via CACNA1F Small molecule Approved Strong 95 DGIdb
AMLODIPINE BESYLATE Repurposing via CACNA1C Small molecule Approved Strong 95 DGIdb
AMLODIPINE MALEATE Repurposing via CACNA1F Small molecule Approved Strong 95 DGIdb
AMPHETAMINE Repurposing via ANXA4 Small molecule Approved Strong 95 ChEMBL
ARGIPRESSIN Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
ARSENIC TRIOXIDE Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
ATENOLOL Repurposing via CACNA1C Small molecule Approved Strong 95 DGIdb
BACLOFEN Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
BEPRIDIL Repurposing via CACNA1A Small molecule Approved Strong 95 DGIdb
BEPRIDIL HYDROCHLORIDE Repurposing via CACNA1G Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
BICALUTAMIDE Repurposing via ANXA4 Small molecule Approved Strong 95 ChEMBL
BORTEZOMIB Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
CAMPTOTHECIN Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
CAPSAICIN Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
CARBACHOL Repurposing via ANXA4 Small molecule Approved Strong 95 ChEMBL
CELECOXIB Repurposing via CACNA1G Small molecule Approved Strong 95
2 pubs
View evidence
DGIdb
CETUXIMAB Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
CHLORPROMAZINE Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
CINNARIZINE Repurposing via CACNA1F Small molecule Approved Strong 95
6 Trial pubs 5 RCT
View evidence

Published literature

DGIdb
CIPROFLOXACIN Repurposing via ANXA4 Small molecule Approved Strong 95 ChEMBL
CITALOPRAM Repurposing via CACNA1C Small molecule Approved Strong 95 DGIdb
CLEVIDIPINE Repurposing via CACNA1F Small molecule Approved Strong 95 DGIdb
CLOMIPRAMINE Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
CLOMIPRAMINE Repurposing via ANXA4 Small molecule Approved Strong 95 ChEMBL
COLCHICINE Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
CORTICOTROPIN Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
DACTINOMYCIN Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
DEHYDRATED ALCOHOL Repurposing via CACNA1C Small molecule Approved Strong 95 DGIdb
DESIPRAMINE Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
DIAZEPAM Repurposing via ANXA4 Small molecule Approved Strong 95
4 Trial pubs 2 RCT
View evidence

Published literature

ChEMBL
DICHLORPHENAMIDE Repurposing via ANXA4 Small molecule Approved Strong 95 ChEMBL
DIDANOSINE Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
DIETHYLSTILBESTROL Repurposing via BDNF Small molecule Approved Strong 95 DGIdb
DIETHYLSTILBESTROL Repurposing via ANXA4 Small molecule Approved Strong 95 ChEMBL
DILTIAZEM HYDROCHLORIDE Repurposing via CACNA1F Small molecule Approved Strong 95 DGIdb

Natural Products

31 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
Ginkgo Biloba Natural product Botanical Phase II Moderate 21
5 trials 20 Cochrane 19 RCT
View evidence

Registry trials

  • NCT05300594 — Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (COMPLETED) NA
  • NCT06124703 — Different Dosing Regimens of STOP-AST (UNKNOWN) NA
  • NCT05591144 — Short-term Oral Prednisone for Acute Subjective Tinnitus (COMPLETED) NA
  • NCT03425045 — Repetitive Transcranial Magnetic Stimulation for Chronic Subjective Tinnitus (COMPLETED) NA
  • NCT01663467 — Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy (WITHDRAWN) NA

Published literature

Examine.com, GreenMedInfo
Zinc Natural product Nutraceutical Phase II Moderate 20
5 trials 5 Trial pubs
View evidence

Registry trials

  • NCT01066273 — Somatosensory Based Treatments for Tinnitus (WITHDRAWN) NA
  • NCT05300594 — Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (COMPLETED) NA
  • NCT05646693 — Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory Cytokines in Patients With Tinnitus (UNKNOWN) PHASE2
  • NCT00683644 — Zinc to Treat Tinnitus in the Elderly (COMPLETED) PHASE2
  • NCT02951715 — Improvement of Tinnitus After Oral Zinc on Patients With Noise-induced Hearing Loss (COMPLETED) NA

Published literature

Examine.com, GreenMedInfo
Magnesium Natural product Nutraceutical Phase III Moderate 20
6 trials
View evidence

Registry trials

  • NCT05300594 — Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (COMPLETED) NA
  • NCT04210310 — High Dose Oxytocin Nasal Spray for Treatment of Tinnitus (TERMINATED) PHASE3
  • NCT01273883 — A Trial of Magnesium Dependent Tinnitus (COMPLETED) PHASE3
  • NCT01727492 — Prevention of Noise-induced Damage by Use of Antioxidants (UNKNOWN) NA
  • NCT05646693 — Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory Cytokines in Patients With Tinnitus (UNKNOWN) PHASE2
  • NCT00808470 — Micronutrients to Prevent Noise-induced Hearing Loss (COMPLETED) PHASE2

Examine.com
Magnesium Natural product Nutraceutical Phase III Emerging 19
6 trials
View evidence

Registry trials

  • NCT05300594 — Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (COMPLETED) NA
  • NCT04210310 — High Dose Oxytocin Nasal Spray for Treatment of Tinnitus (TERMINATED) PHASE3
  • NCT01273883 — A Trial of Magnesium Dependent Tinnitus (COMPLETED) PHASE3
  • NCT01727492 — Prevention of Noise-induced Damage by Use of Antioxidants (UNKNOWN) NA
  • NCT05646693 — Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory Cytokines in Patients With Tinnitus (UNKNOWN) PHASE2
  • NCT00808470 — Micronutrients to Prevent Noise-induced Hearing Loss (COMPLETED) PHASE2

Examine.com
Zinc Natural product Nutraceutical Phase II Emerging 19
5 trials 5 Trial pubs
View evidence

Registry trials

  • NCT01066273 — Somatosensory Based Treatments for Tinnitus (WITHDRAWN) NA
  • NCT05300594 — Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (COMPLETED) NA
  • NCT05646693 — Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory Cytokines in Patients With Tinnitus (UNKNOWN) PHASE2
  • NCT00683644 — Zinc to Treat Tinnitus in the Elderly (COMPLETED) PHASE2
  • NCT02951715 — Improvement of Tinnitus After Oral Zinc on Patients With Noise-induced Hearing Loss (COMPLETED) NA

Published literature

Examine.com
Melatonin Natural product Nutraceutical Preclinical Moderate 17
1 trials 8 Trial pubs
View evidence

Registry trials

  • NCT05300594 — Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (COMPLETED) NA

Published literature

Examine.com, GreenMedInfo
Melatonin Natural product Nutraceutical Phase I Emerging 10
1 trials 8 Trial pubs
View evidence

Registry trials

  • NCT05300594 — Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (COMPLETED) NA

Published literature

Examine.com
Vitamin D3 Natural product Nutraceutical Preclinical Emerging 10
1 Trial pubs 1 RCT
View evidence
GreenMedInfo
Vitamin B12 Natural product Nutraceutical Preclinical Emerging 10
1 trials 5 Trial pubs 4 RCT
View evidence

Registry trials

  • NCT05300594 — Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (COMPLETED) NA

Published literature

GreenMedInfo
Folate Natural product Nutraceutical Preclinical Emerging 10
2 pubs
View evidence
GreenMedInfo
Vitamin C Natural product Nutraceutical Phase II Emerging 10
2 trials 3 Trial pubs 1 RCT
View evidence

Registry trials

  • NCT05646693 — Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory Cytokines in Patients With Tinnitus (UNKNOWN) PHASE2
  • NCT00808470 — Micronutrients to Prevent Noise-induced Hearing Loss (COMPLETED) PHASE2

Published literature

GreenMedInfo
Vitamin E Natural product Nutraceutical Phase II Emerging 10
2 trials 3 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT05646693 — Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory Cytokines in Patients With Tinnitus (UNKNOWN) PHASE2
  • NCT00808470 — Micronutrients to Prevent Noise-induced Hearing Loss (COMPLETED) PHASE2

Published literature

GreenMedInfo
Spirulina Natural product Nutraceutical Preclinical Emerging 7
1 trials 2 Cochrane
View evidence

Registry trials

  • NCT06997406 — 'Inner Ear Support' Oral Capsule in Patients With Sudden Sensorineural Hearing Loss (NOT_YET_RECRUITING) NA

Published literature

GreenMedInfo
Alpha-Lipoic Acid Natural product Nutraceutical Phase II Emerging 7
1 trials 1 Cochrane 1 Trial pubs 1 RCT
View evidence

Registry trials

  • NCT04105426 — A Study on the Effectiveness of Antioxidant Supplementation in Tinnitus (COMPLETED) PHASE2

Published literature

GreenMedInfo
Niacin Natural product Nutraceutical Preclinical Emerging 7
1 trials
View evidence

Registry trials

  • NCT05300594 — Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (COMPLETED) NA

GreenMedInfo
Coenzyme Q10 Natural product Nutraceutical Preclinical Emerging 7
1 trials 1 Trial pubs
View evidence

Registry trials

  • NCT02353650 — The Effect of Coenzyme Q10 on Hearing and Tinnitus Characteristics of Chronic Tinnitus Patients (UNKNOWN) NA

Published literature

GreenMedInfo
Resveratrol Natural product Food compound Preclinical Emerging 7
5 pubs
View evidence
GreenMedInfo
Flavonoids Natural product Nutraceutical Preclinical Emerging 0
1 trials
View evidence

Registry trials

  • NCT06718452 — Tinnitus and Treatment With umPEA-LUT (NOT_YET_RECRUITING) NA

GreenMedInfo
Riboflavin (Vitamin B-2) Natural product Nutraceutical Preclinical Emerging 0
No indexed hits
View evidence
GreenMedInfo
Vitamin a Natural product Food compound Preclinical Emerging 0
No indexed hits
View evidence
GreenMedInfo
Vitamin B-3 (Niacin) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Antioxidant Formulas Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
St. John's Wort Natural product Botanical Preclinical Emerging 0 GreenMedInfo
Ginseng (Korean) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Manganese Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Acai Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Pycnogenol (Pine Bark) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Nettle Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Rose Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Tansy Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Phycocyanin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
VitalScan4PACVS Remote physiological monitoring study for post-acute COVID-19 vaccination syndrome.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.